Navigation Links
Biotech collaboration established to commercialize research reagents
Date:10/18/2010

The Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, has entered a collaboration with New Jersey-based medical technology company BD to evaluate and potentially develop for research and diagnostic use some of the institute's reagents.

The institute has a portfolio of more than 100 monoclonal antibodies produced through its in-house antibody facility for research into cancer, chronic inflammatory diseases and infectious diseases.

The collaboration, with BD's Biosciences segment, will build on programs at the institute that are focused on identifying novel targets for therapeutic monoclonal antibody and drug development.

Under the terms of the agreement, BD will make upfront and annual payments to the institute as well as royalty payments on sales of any licensed antibodies in return for a first option to evaluate and commercialise antibodies from the institute. The financial terms of the collaboration are confidential.

The institute's business development manager Dr James Dromey said antibodies were an important tool in the lab as well as the clinic, where they are used as diagnostic tools and biomarkers.

"This is a wonderful opportunity for the institute to share its internal resources and scientific expertise with the wider scientific community and to improve the possibility of the institute's technology being commercialised and having a positive impact on research and diagnostic markets," Dr Dromey said.

"The institute's strategic research interests align well with those of BD, particularly in key areas such as cancer, programmed cell death (apoptosis), stem cells and immunology. This is the first commercial contract that we have established for wider utilisation of institute reagents, and we hope it will be the first step in a broader collaboration with BD."

The institute has a track record for producing commercially available and successful products, including the LIF protein, which is essential for the maintenance of embryonic stem cells, and the pGex fusion protein vector.

Antibody production and related services form one of the most important technology platforms that underpin the institute's successful science and commercialisation activities. The institute's 'discovery pipeline' is fed by more than 250 research projects, many involving development of new antibodies through its in-house antibody facility.


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Related biology news :

1. Developments in nanobiotechnology at UCSB point to medical applications
2. New biotech company grows from MCG diabetes and genomic research
3. $31 million biotech center to benefit crops, food, energy
4. Success with cisgenics in forestry offers new tools for biotechnology
5. Cutting-edge vaccine research to be showcased at AAPS National Biotechnology Conference
6. Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference
7. AAPS immunogenicity training course to be offered prior to national biotechnology conference
8. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
9. NYU School of Medicine presents biomedical researchers Dart/NYU Biotechnology Achievement Awards
10. GenWay Biotech extends the You Test You program overseas
11. New biotech advance to add heart healthy omega-3s to US diet
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biotech collaboration established to commercialize research reagents
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Dutch philosopher Koert van Mensvoort ... Nature, at the University of Technology in Eindhoven - has written a ... letter, he calls on humanity to avoid becoming a slave and victim to ... ... Dutch philosopher Koert van Mensvoort – founder of the Next ...
(Date:4/20/2017)... 2017 For today, Stock-Callers.com redirects investors, ... development and clinical research aimed at treating diseases and medical ... Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), ... can access our complimentary research reports on these stocks now ... http://stock-callers.com/registration ...
(Date:4/19/2017)... Ca (PRWEB) , ... April 18, 2017 , ... A ... technological advances. This webinar, which is part of the Protein and Cell Analysis ... Cytometer and outline where this technology fits in current and future applications. , ...
(Date:4/19/2017)... ... April 18, 2017 , ... ... Labs . The move comes after the company changed focus to making analytical ... new brand and our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, ...
Breaking Biology Technology: